Healthcare professionals and patients should report any suspected adverse reactions through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app), contributing to the ongoing safety profile assessment of this medication
Development Updates on Danuglipron However, due to potential liver toxicity effects, Pfizer, the developer of danuglipron, has discontinued its efforts to license the drug candidate
1) Kesimpta (ofatumumab) (PG225, Ver
It inhibits bacterial protein synthesis by binding in the 50S ribosomal subunit and blocking the egress of polypeptide chains
[34] showed that treatment with the GLP-1 RAs exenatide and liraglutide reduced both systolic and diastolic BP by 1 to 5 mm Hg in patients with T2D, compared with some other anti-diabetic drugs, including insulin, glimepiride, and placebo
If you are unsure if what you are feeling is "normal," or if you just need a second opinion on your symptoms, do not guess